FPR1 and Hypertension: Extending these observations beyond ischemic remodeling, a biased small-molecule FPR1/2 agonist (compound 17b; Cmpd17b) has also been shown to mitigate hypertension-driven CV injury in an angiotensin II—induced model [145].